BRD-K98645985

BRD-K98645985 Chemische Eigenschaften,Einsatz,Produktion Methoden

• Definition

  ChEBI: 1-[(4S,7S,8R)-8-methoxy-4,7,10-trimethyl-11-oxo-5-[[4-(2-pyridinyl)phenyl]methyl]-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-3-propan-2-ylurea is an azamacrocycle and a lactam.

• Biologische Aktivität

  BRD-K98645985 is an inhibitor of BAF (mammalian SWI/SNF) transcriptional repression with EC50 of ~2.37 μM. It binds ARID1A-specific BAF complexes, prevents nucleosome localization, and potently reverses HIV-1 latency without T cell toxicity.

• in vitro

  BRD-K98645985 (30 μM; 18 hours) treatment shows a 5-fold increase in Bmi1 , 2.6-fold increase in Ring1 , and 3.3- fold decrease in Fgf4 .
  BRD-K98645985 treatment shows a concentration dependent latency reversal in J-Lat T-cell line models. BRD-K98645985 can be combined with other LRAs to improve reservoir targeting.

• target

  BAF transcriptional repression < span> 2.37 μM (EC 50 )

  HIV-1

BRD-K98645985 Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

Global(25)Suppliers